Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Eisai Racks Up 5.9% Sales Increase in April-September on Lenvima Growth, Despite Price Cuts, COVID-19
Eisai’s group sales rose 5.9% in the first half of FY2020, propped up by the robust performance of its anticancer agent Lenvima (lenvatinib), despite the negative factors such as drug price revisions and the COVID-19 pandemic, according to its earnings…
To read the full story
Related Article
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Eisai’s Q1 Operating Profit Jumps on Lenvima Growth, Lower Aduhelm Cost
August 3, 2023
- Eisai’s FY2022 Sales Slip 1.6% on Lower Milestones, Year-Before Gain
May 16, 2023
- Eisai Cuts FY2022 Earnings Forecast on FX, Subpar Mainstay Results
May 10, 2023
- Eisai’s 9-Month Profits Sink after One-Time BMS Alliance Gain a Year Ago
February 7, 2023
- Eisai Scores Sales, Profit Growth on Lenvima Boon in FY2021 despite Aduhelm Setback
May 16, 2022
- Eisai’s April-December Sales Zoom 13.4% on Lenvima Growth Overseas
February 4, 2022
- Eisai’s H1 Sales Rise 14.3% on 4 Global Brands, ADC License Income
November 2, 2021
- Eisai Logs 58.8% Drop in Operating Profit as Merck Milestone Dips on Lenvima Miss
May 13, 2021
- Eisai’s April-December Profits Slip on Aggressive Investments
February 4, 2021
- Before Aducanumab AdCom, Eisai CEO Voices Hopes for Potential 1st Alzheimer’s Drug in 17 Years
November 6, 2020
BUSINESS
- Sanwa, Nissan Chemical to Jointly Develop Oligonucleotide for DRPLA in Japan
April 8, 2025
- Hong Kong Fund Oasis Sues Kobayashi Execs over Beni-Koji Scandal
April 8, 2025
- Japan Ethical Drug Sales Down 5.1% in February: Crecon
April 8, 2025
- Santen’s Glaucoma Drug Tapcom Snags China Approval
April 7, 2025
- Sanofi Launches Epidemiological Study for Beyfortus in Japan
April 7, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…